MET and non-small cell lung carcinoma: Previously, we identified CBZ, a c-Met and VEGFR2 inhibitor, as a novel modulator of ABCG2 with the capability of reversing resistance to mitoxantrone, SN-38, and TPT without affecting ABCG2 protein expression in NSCLC cells (Zhang G.N. et al., 2017).